Goldman Sachs Says it Sees Prostate Cancer as an Attractive Strategic Opportunity

According to Goldman Sachs, Amgen

Sell rating is maintained. Goldman Sachs said that is sees prostate cancer as an attractive strategic opportunity. “Our Sell rating and $50, 12-month DCF-derived price target are unchanged.” Amgen closed yesterday at $57.62.